查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587126

循環性腫瘤細胞市場：依檢體、技術、產品、應用分類 - 2025-2030 年全球預測

Circulating Tumor Cell Market by Specimen (Blood, Bone Marrow), Technology (CTC Analysis, CTC Detection & Enrichment Methods, CTC Direct Detection Methods), Product, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

循環性腫瘤細胞市場2023年估值為124.4億美元，預計2024年將達到141.7億美元，複合年成長率為13.99%，預計到2030年將達到311.2億美元。

循環性腫瘤細胞（CTC）是重要的非侵入性生物標記物，可顯著改善癌症診斷、預後和治療效果的預測。 CTC 分析市場是由早期癌症檢測、個人化醫療和疾病監測應用的迫切需求所推動的，考慮到向精準醫療的轉變，該市場尤其有前景。醫院、診斷實驗室和研究機構等最終用途部門正在尋求 CTC 技術作為傳統切片檢查方法的潛在替代品。主要成長動力包括癌症發生率上升、檢測技術的進步以及研究投資的增加。市場正在見證利用人工智慧改進 CTC 檢測和建立用於預測分析的綜合資料庫的新興機會。然而，高成本、技術複雜性和標準化問題等挑戰仍然是市場成長的主要障礙。檢測技術有限的敏感度和特異性也仍然是一個障礙，常常導致檢測不足和誤報。此外，監管和道德考慮因素極大地影響市場動態，使核准和市場准入變得複雜。儘管存在這些挑戰，但在開發具有成本效益且靈敏的檢測方法以及整合多組體學方法以獲得全面見解方面仍然存在大量創新機會。微流體、奈米技術的創新和分子檢測的進步被認為是可以推動市場擴張的有前景的領域。此外，促進生物技術公司、研究機構和醫療保健提供者之間的策略合作可以促進更廣泛的技術採用和穩健的通訊協定開發。此外，基於聚合物的捕獲劑和疾病管理整合平台的出現代表了潛在的成長途徑。總體而言，CTC 市場具有動態性，其特點是技術快速進步和應用領域多樣化，但市場的永續性取決於在解決當前限制的同時利用新的突破，並取決於建立可提高臨床結果和市場滲透率的夥伴關係。市場相關人員必須保持敏捷，才能利用這些不斷變化的機會。

主要市場統計
基準年[2023] 124.4億美元
預測年份 [2024] 141.7億美元
預測年份 [2030] 311.2億美元
複合年成長率（%） 13.99%

市場動態：揭示快速發展的循環性腫瘤細胞市場的關鍵市場洞察

供需的動態交互作用正在改變循環性腫瘤細胞市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症相關治療的支出增加
    • 全球癌症盛行率
    • 提高對癌症早期發現的認知和關注
  • 市場限制因素
    • 對CTC系統缺乏認知
  • 市場機會
    • 生物技術和生物醫學的技術進步
    • 近年來微創診斷的需求
  • 市場挑戰
    • 政府對 CTC 技術核准的嚴格規定

波特五力：駕馭循環性腫瘤細胞市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解循環性腫瘤細胞市場的外部影響

外部宏觀環境因素在塑造循環性腫瘤細胞市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解循環性腫瘤細胞市場的競爭格局

循環性腫瘤細胞市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣循環性腫瘤細胞市場供應商的績效評估

FPNV 定位矩陣是評估循環性腫瘤細胞市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃循環性腫瘤細胞市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對循環性腫瘤細胞市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症相關治療的支出增加
      • 世界各地癌症發生率
      • 提高對癌症早期發現的認知和關注
    • 抑制因素
      • 對CTC系統缺乏認知
    • 機會
      • 生物工程和生物醫學實踐的技術進步
      • 近年來微創診斷的需求
    • 任務
      • CTC技術核准有嚴格的政府法規
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 樣本循環性腫瘤細胞市場

  • 血
  • 骨髓

第7章循環性腫瘤細胞市場：依技術分類

  • CTC分析
  • CTC檢測和富集方法
    • 組合法
    • 基於密度的分離
    • 免疫捕獲
      • 消極選擇
      • 正向選擇
    • 根據尺寸分離
      • 基於膜的
      • 基於微流體
  • CTC直接檢測法
    • 顯微鏡檢查
    • 非典

第8章循環性腫瘤細胞市場：依產品

  • 採血管
  • 設備或系統
  • 試劑套件和試劑

第9章循環性腫瘤細胞市場：依應用分類

  • 臨床/液態生物檢體
    • 風險評估
    • 篩檢和監測
  • 調查
    • 癌症幹細胞和腫瘤形成研究
    • 藥物或治療方法的開發

第10章美洲循環性腫瘤細胞市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太循環性腫瘤細胞市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲循環性腫瘤細胞市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • BioFluidica
  • Biolidics Limited
  • Creatv MicroTech, Inc.
  • Epic Sciences
  • Fluxion Biosciences, Inc.
  • Greiner Bio One International GmbH
  • Ikonisys Inc.
  • IVDiagnostics
  • LungLife AI, Inc.
  • Menarini Silicon Biosystems
  • Miltenyi Biotec GmbH
  • NanoString Technologies, Inc.
  • Precision Medicine Group, LLC
  • QIAGEN GmbH
  • Rarecells Diagnostics
  • ScreenCell
  • STEMCELL Technologies, Inc.
  • Sysmex Corporation
  • Vitatex, Inc
Product Code: MRR-A339DAEF9F97

The Circulating Tumor Cell Market was valued at USD 12.44 billion in 2023, expected to reach USD 14.17 billion in 2024, and is projected to grow at a CAGR of 13.99%, to USD 31.12 billion by 2030.

Circulating Tumor Cells (CTCs) offer a critical non-invasive biomarker that can significantly enhance cancer diagnostics, prognosis, and therapeutic efficacy predictions. The market for CTC analysis is driven by the urgent necessity for early cancer detection, personalized medicine, and disease monitoring applications, which hold particular promise given the shift towards precision medicine. End-use sectors like hospitals, diagnostic labs, and research institutions are pursuing CTC technologies for their potential to replace conventional biopsy methods. Key growth drivers include rising cancer prevalence, advances in detection technologies, and increased investment in research. The market is witnessing burgeoning opportunities in utilizing artificial intelligence for improved CTC detection and building comprehensive databases for predictive analytics. Nevertheless, challenges such as high costs, technical complexities, and standardization issues stand as significant barriers to market growth. Limited sensitivity and specificity of detection techniques remain a hurdle, often leading to under-detection or false positives. Furthermore, regulatory and ethical considerations significantly influence market dynamics, complicating approvals and market entry. Despite these challenges, innovation opportunities abound in developing cost-effective, highly sensitive detection methods and integrating multi-omics approaches for comprehensive insights. Innovations in microfluidics, nanotechnology, and molecular assay advancements are identified as promising areas that could propel market expansion. Moreover, fostering strategic collaborations across biotechnology firms, research entities, and healthcare providers could facilitate wider technology adoption and robust protocol development. Furthermore, the emergence of polymer-based capture substances and integrated platforms for disease management exemplify potential avenues for growth. Overall, the CTC market carries a dynamic nature characterized by rapid technological advancements and diverse application fields, but market sustainability will depend on addressing current limitations while harnessing new breakthroughs and forming partnerships that enhance clinical outcomes and market penetration. Market actors need to maintain agility to capitalize on these evolving opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 12.44 billion
Estimated Year [2024] USD 14.17 billion
Forecast Year [2030] USD 31.12 billion
CAGR (%) 13.99%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Circulating Tumor Cell Market

The Circulating Tumor Cell Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased spending in cancer-related therapies
    • Prevalence of cancer across the globe
    • Rising awareness and focus on early cancer detection
  • Market Restraints
    • Lack of awareness about CTC systems
  • Market Opportunities
    • Technological advancements in bioengineering and biomedical practices
    • Demand for minimally invasive diagnostics in recent years
  • Market Challenges
    • Stringent government regulations for the approval of CTC technologies

Porter's Five Forces: A Strategic Tool for Navigating the Circulating Tumor Cell Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Circulating Tumor Cell Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Circulating Tumor Cell Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Circulating Tumor Cell Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Circulating Tumor Cell Market

A detailed market share analysis in the Circulating Tumor Cell Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Circulating Tumor Cell Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Circulating Tumor Cell Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Circulating Tumor Cell Market

A strategic analysis of the Circulating Tumor Cell Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Circulating Tumor Cell Market, highlighting leading vendors and their innovative profiles. These include BioFluidica, Biolidics Limited, Creatv MicroTech, Inc., Epic Sciences, Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., IVDiagnostics, LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec GmbH, NanoString Technologies, Inc., Precision Medicine Group, LLC, QIAGEN GmbH, Rarecells Diagnostics, ScreenCell, STEMCELL Technologies, Inc., Sysmex Corporation, and Vitatex, Inc.

Market Segmentation & Coverage

This research report categorizes the Circulating Tumor Cell Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Specimen, market is studied across Blood and Bone Marrow.
  • Based on Technology, market is studied across CTC Analysis, CTC Detection & Enrichment Methods, and CTC Direct Detection Methods. The CTC Detection & Enrichment Methods is further studied across Combined Methods, Density-Based Separation, Immunocapture, and Size-Based Separation. The Immunocapture is further studied across Negative Selection and Positive Selection. The Size-Based Separation is further studied across Membrane-Based and Microfluidic-Based. The CTC Direct Detection Methods is further studied across Microscopy and SERS.
  • Based on Product, market is studied across Blood Collection Tubes, Devices or Systems, and Kits & Reagents.
  • Based on Application, market is studied across Clinical/ Liquid Biopsy and Research. The Clinical/ Liquid Biopsy is further studied across Risk Assessment and Screening & Monitoring. The Research is further studied across Cancer Stem Cell & Tumorigenesis Research and Drug or Therapy Development.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased spending in cancer-related therapies
      • 5.1.1.2. Prevalence of cancer across the globe
      • 5.1.1.3. Rising awareness and focus on early cancer detection
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness about CTC systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in bioengineering and biomedical practices
      • 5.1.3.2. Demand for minimally invasive diagnostics in recent years
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for the approval of CTC technologies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Circulating Tumor Cell Market, by Specimen

  • 6.1. Introduction
  • 6.2. Blood
  • 6.3. Bone Marrow

7. Circulating Tumor Cell Market, by Technology

  • 7.1. Introduction
  • 7.2. CTC Analysis
  • 7.3. CTC Detection & Enrichment Methods
    • 7.3.1. Combined Methods
    • 7.3.2. Density-Based Separation
    • 7.3.3. Immunocapture
      • 7.3.3.1. Negative Selection
      • 7.3.3.2. Positive Selection
    • 7.3.4. Size-Based Separation
      • 7.3.4.1. Membrane-Based
      • 7.3.4.2. Microfluidic-Based
  • 7.4. CTC Direct Detection Methods
    • 7.4.1. Microscopy
    • 7.4.2. SERS

8. Circulating Tumor Cell Market, by Product

  • 8.1. Introduction
  • 8.2. Blood Collection Tubes
  • 8.3. Devices or Systems
  • 8.4. Kits & Reagents

9. Circulating Tumor Cell Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical/ Liquid Biopsy
    • 9.2.1. Risk Assessment
    • 9.2.2. Screening & Monitoring
  • 9.3. Research
    • 9.3.1. Cancer Stem Cell & Tumorigenesis Research
    • 9.3.2. Drug or Therapy Development

10. Americas Circulating Tumor Cell Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Circulating Tumor Cell Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Circulating Tumor Cell Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. BioFluidica
  • 2. Biolidics Limited
  • 3. Creatv MicroTech, Inc.
  • 4. Epic Sciences
  • 5. Fluxion Biosciences, Inc.
  • 6. Greiner Bio One International GmbH
  • 7. Ikonisys Inc.
  • 8. IVDiagnostics
  • 9. LungLife AI, Inc.
  • 10. Menarini Silicon Biosystems
  • 11. Miltenyi Biotec GmbH
  • 12. NanoString Technologies, Inc.
  • 13. Precision Medicine Group, LLC
  • 14. QIAGEN GmbH
  • 15. Rarecells Diagnostics
  • 16. ScreenCell
  • 17. STEMCELL Technologies, Inc.
  • 18. Sysmex Corporation
  • 19. Vitatex, Inc

LIST OF FIGURES

  • FIGURE 1. CIRCULATING TUMOR CELL MARKET RESEARCH PROCESS
  • FIGURE 2. CIRCULATING TUMOR CELL MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CIRCULATING TUMOR CELL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CIRCULATING TUMOR CELL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CIRCULATING TUMOR CELL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CIRCULATING TUMOR CELL MARKET DYNAMICS
  • TABLE 7. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COMBINED METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DENSITY-BASED SEPARATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY NEGATIVE SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY POSITIVE SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY MEMBRANE-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY MICROFLUIDIC-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY BLOOD COLLECTION TUBES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DEVICES OR SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY SCREENING & MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER STEM CELL & TUMORIGENESIS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG OR THERAPY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 245. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 246. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 255. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 256. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 265. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 266. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 275. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 276. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 285. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 286. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 295. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 296. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 305. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 306. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY SPECIMEN, 2018-2030 (USD MILLION)
  • TABLE 316. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ENRICHMENT METHODS, 2018-2030 (USD MILLION)
  • TABLE 318. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOCAPTURE, 2018-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY SIZE-BASED SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DIRECT DETECTION METHODS, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL/ LIQUID BIOPSY, 2018-2030